Does Endotrophin (P-ETP) predict cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes?
Endotrophin (P-ETP) is a risk marker that predicts cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes, potentially useful for patient enrichment in future trials.
P-ETP generated during COL VI formation predicts cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes. As ETP identifies patients at increased risk of experiencing relevant outcomes, it may be used for patient enrichment in future clinical trials. Trial Registry Number (ClinicalTrials.gov Identifier): NCT01032629.
Rasmussen et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: